The Arizona Revised Statutes have been updated to include the revised sections from the 57th Legislature, 2nd Regular Session. Please note that the next update of this compilation will not take place until after the conclusion of the 58th Legislature, 1st Regular Session, which convenes in January 2027.
This online version of the Arizona Revised Statutes is primarily maintained for legislative drafting purposes and reflects the version of law that is effective on January 1st of the year following the most recent legislative session. The official version of the Arizona Revised Statutes is published by Thomson Reuters.
36-121.01. Childhood cancer and rare childhood disease research commission; membership; reimbursement; conflict of interest; annual report
A. Subject to the conditions specified in section 36-121, subsection B, the childhood cancer and rare childhood disease research commission is established consisting of at least the following members who are appointed by the director:
1. One member who is a survivor of childhood cancer or a caregiver to individuals who have childhood cancer.
2. One member who is a survivor of a rare childhood disease or a caregiver to individuals who have rare childhood diseases.
3. Four health professionals who practice in the field of either pediatric cancer or rare childhood diseases.
4. One member who represents a nationwide pediatric cancer advocacy nonprofit organization.
B. Commission members shall serve five-year terms and shall annually elect a chairperson from the membership. Commission members are not eligible to receive compensation but are eligible for reimbursement of expenses pursuant to title 38, chapter 4, article 2.
C. The commission shall:
1. Establish criteria for the clinical trials that qualify to receive research grants.
2. Oversee the application process and review applications for the clinical trial research grants to assist the director in selecting the most credible clinical trials to which to award the research grants.
3. Ensure that all commission meetings are open to the public and allow for public testimony.
D. The director shall award grants to health care providers and research institutions that are located in this state, that are nonprofit organizations and that are engaged in clinical trials relating to research on pediatric cancer or other rare pediatric diseases. The monies awarded may be used in a collaborative study or research program with other facilities outside of this state. Nonprofit organizations that receive monies from the childhood cancer and rare disease research fund established by section 36-121 shall use the monies for the purposes prescribed in this subsection even if the monies are aggregated with other monies.
E. Commission members shall recuse themselves from discussing and voting on any matter in which they have a conflict of interest. If at any time commission member recusals due to conflicts of interest cause the commission to no longer have a quorum to take official action, the director or the director's designee and other department staff members appointed by the director may act as members of the commission on any grant application at issue.
F. Not later than August 1, 2027 and August 1 of each year thereafter, the commission shall submit a report to the appropriations committees and health and human services committees of the senate and the house of representatives, or their successor committees, detailing the number, amounts and recipients of the grants awarded pursuant to this section, the resulting research and any other relevant information.